Forbion closes oversubscribed BioEconomy Fund I at €200 Million Hard Cap

Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announced that its Forbion BioEconomy Fund I has reached its hard cap of €200 million. Targeting investments at the nexus of biotechnology and planetary health, the fund stands as one of Europe’s largest dedicated bioeconomy funds, extending Forbion’s vision of supporting sustainable technologies that can contribute to the decarbonizing of multiple industries.

Launched in 2024 with an initial target of €150 million, Forbion BioEconomy Fund I attracted strong support from institutional investors across Europe and North America including KfW Capital, Novo Holdings, Rentenbank, Aurae Impact, ABN AMRO Bank and EIFO. The fund invests in biotechnologies and green chemistries that make industrial sustainability scalable. Its portfolio includes eeden, Genomines, SOLASTA Bio, Novameat, and PACT, all developing transformative solutions across the Fund’s four strategic priority sectors of Food, Agriculture, Materials and Environmental Technologies.